Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX51107 and Azacitidine in AML and MDS
NCT04022785Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PLX51107 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Myeloproliferative Neoplasm (MPN), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of Adverse Events at 5 years and Minimum Safe and Biologically Effective Dose at 28 days. Started Sep 2019; status: completed.
02
Drugs
PLX51107
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT04022785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04022785.